

## 2015-2016 American Heart Association Support from Pharmaceutical Companies and Device Manufacturers

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 20.8 percent of the AHA's \$863,355,000 in total revenue (2015-2016 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 5.8 percent of the association's total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2015-2016, noting that, in some cases, the funds will be received in future years.



NOTE: The Pie Chart above shows income committed in fiscal year 2015-2016 to the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers during fiscal year 2015-2016.

In addition, in the right column, we have listed revenue that was committed to the American Heart Association during fiscal year 2015-2016, but will be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

FY 2015-2016 Contributed Income and Other Revenue Raised at the National Level from Pharmaceutical Companies and Medical Device Manufacturers		
Corporation	Total Cash Received During FY 2015-2016 on Prior and Current Year Commitments (1)	Current Year FY 2015-2016 Commitments Receivable in the Future
Abbott Diagnostics	42,500	-
Abbott Laboratories	15,000	-
Abbott Vascular	-	-
Amarin	60,000	-
Amerihealth Caritas Keystone First	-	125,000
Amgen	3,616,000	1,500,000
Anthem	1,709,624	75,000
Aralez Pharmaceuticals	-	65,000
Arthrex	100,000	-
AstraZeneca	12,292,500	15,075,000
Bayer Healthcare	683,975	-
Biotronik, Inc.	62,500	62,500
Blue Cross Blue Shield	170,000	-
BMS/Pfizer	1,841,000	-
Boehringer Ingelheim Pharmaceuticals	252,095	60,000
Carefirst BlueCross BlueShield	-	225,000
Chiesi	150,000	-
Cigna	-	-
CPR Working Group	60,000	-
Daiichi Sankyo	600,000	65,000
Edwards Lifesciences LLC	550,000	150,000
Eli Lilly	75,000	-
Genentech	10,300	-
Gilead Sciences	98,915	-
GlaxoSmithKline	-	25,000
ISIS Pharmaceuticals, Inc.	2,500	-
Janssen	915,000	500,000
Laerdal Medical Corporation	15,000	-
Medtronic/Covidien/EV3	2,855,960	3,131,503
Merck	275,000	22,500
Mitsubishi Tanabe	4,108	-
NICO	25,000	-
Novartis Pharmaceuticals	330,000	1,352,298
Pfizer	1,035,000	-
Philips Healthcare	330,000	-
Physio-Control	22,500	15,000
Pozen	30,000	-
Regeneron	100,000	-
Relypsa	140,000	145,000
Sanofi	565,000	215,000
Sanofi-Regeneron	-	5,357,122
Stryker Neurovascular	53,625	-
Takeda Pharmaceutical Company Limited	(18,773)	-
The Medicines Company	30,150	-
Transamerica	-	1,570,000
WorldPoint	7,500	2,500
Zoll Medical	15,000	-
Zontivity	20,000	-
ZS Pharma	205,000	15,000
<b>Totals</b>	<b>29,346,980</b>	<b>29,753,423</b>

NOTE: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate. Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2011-12, FY 2012-13, FY 2013-14, FY 2014-15, FY2015-16.